Portola’s AANNEXA-4 interim results featured at ESC Congress

Portola Pharmaceuticals Inc. has announced that the Late-Breaking Science Hot Line session at the European Society of Cardiology (ESC) 2016 Congress featured the interim results of its ongoing Phase 3b/4 ANNEXA-4 clinical trial of AndexXa (andexanet alfa).

The ESC Congress is currently taking place in Rome, Italy, until Aug. 31. Portola’s AndexXa results was also highlighted during the ESC’s Hot Line – Preventive Strategies II press conference at 9 a.m. on Aug. 30.

Portola hosted an event for their investors during a webcast on Aug. 30 that followed the presentation of the ANNEXA-4 trial interim results at the ESC Congress, with members from the Portola senior management team. These members, who presented and discussed the data, included Dr. Stuart J. Connolly, Executive Committee chairman of ANNEXA-4, and ANNEXA-4 Executive Committee member Dr. C. Michael Gibson.

The oral presentation, titled “ANNEXA-4 — Andexanet alfa for reversal of Factor Xa inhibitors in patients with acute major bleeding,” took place on Aug. 30 at the Fiera di Roma Exhibition and Trade Centre in Rome and was presented by Dr. Stuart J. Connolly, Professor in the Department of Medicine at McMaster University in Ontario. The webcast featuring Portola’s senior management team took place at the conclusion of the presentation.